Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gencurix Inc. manages a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This 1 pending office action is assigned to 1 distinct examiner, meaning the company's current biological claims are under the review of a single individual. This prosecution activity is located within 1 distinct art unit.
The busiest examiner identified is SITTON, JEHANNE SOUAYA, who handles 1 busiest examiner pending office action. Because the total number of pending office actions is 1, SITTON, JEHANNE SOUAYA is the sole USPTO official responsible for the current workload. This creates a direct line of interaction between the applicant and the examiner within the Biotechnology & Pharmaceuticals sector.
Practitioners should observe that with 1 distinct examiner and 1 distinct art unit, there is no opportunity to compare different examination styles within the current portfolio. The progress of the 1 pending office action will be subject to the specific interpretations and requirements of SITTON, JEHANNE SOUAYA. This focused structure requires a response strategy that addresses the particular standards of the single art unit involved in the biotechnology field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | SITTON, JEHANNE SOUAYA | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | SITTON, JEHANNE SOUAYA | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | SITTON, JEHANNE SOUAYA | 1682 | §101§112 | Final Rejection | 31d overdue | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGencurix Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jehanne Souaya Sitton has the most, with 1 of Gencurix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
